Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
KontRASt-01 trial: what clinicians have said so far
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
- NCT04699188 ↗
- Active, not recruiting
- Novartis Pharmaceuticals
- Standard size, estimated: 151–300 verified statements
We haven't built an HCP commentary report on KontRASt-01 (opnurasib (JDQ443); opnurasib (JDQ443) plus TNO155; opnurasib (JDQ443) plus tislelizumab in advanced KRAS G12C-mutated solid tumors) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on KontRASt-01 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 13 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small-Cell Lung; Carcinoma, Colorectal; Cancer of Lung; Cancer of the Lung; Lung Cancer; Neoplasms, Lung; Neoplasms, Pulmonary; Pulmonary Cancer; Pulmonary Neoplasms
- Interventions
- JDQ443; TNO155; tislelizumab
- Arms
- Arm A · Experimental
- Arm B · Experimental
- Arm C · Experimental
- Arm D · Experimental
- Enrollment
- 344
- Primary outcomes
- Dose Escalation: Incidence and severity of dose limiting toxicities (DLTs) during the first cycle of monotherapy or combination treatment
- Dose Escalation: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
- Dose Escalation: Frequency of dose interruptions and reductions, by treatment
- Dose Escalation: Dose intensity by treatment
- Dose Expansion: Overall response rate (ORR) per RECIST v1.1, by treatment
- Dose expansion: Overall intracranial response rate (OIRR) per mRANO-BM
- Dose expansion: Incidence and severity of AEs and SAEs
- Dose expansion: frequency of dose interruptions and reductions, by treatment
- Dose expansion: Dose intensity by treatment
- Dose expansion: ORR per RECIST 1.1 of JDQ443 single agent in patients with non-small cell lung cancer (JDQ443 dose randomization group only)
- Sponsor
- Novartis Pharmaceuticals
- Start
- Feb 24, 2021
- Primary completion
- Jan 25, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04699188 · updated Oct 19, 2026
Publications
linked from the registry- Lorthiois E, Gerspacher M, Beyer KS, Vaupel A, Leblanc C, Stringer R, Weiss A, Wilcken R, Guthy DA, Lingel A, Bomio-Confaglia C, Machauer R, Rigollier P, Ottl J, Arz D, Bernet P, Desjonqueres G, Dussauge S, Kazic-Legueux M, Lozac'h MA, Mura C, Sorge M, Todorov M, Warin N, Zink F, Voshol H, Zecri FJ, Sedrani RC, Ostermann N, Brachmann SM, Cotesta S. JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRASG12C for the Treatment of Solid Tumors. J Med Chem. 2022 Dec 22;65(24):16173-16203. doi: 10.1021/acs.jmedchem.2c01438. Epub 2022 Nov 18. PubMed 36399068